Noul releases AI-based diagnostic gizmo for cervical cancer

Noul Co., a South Korean company specializing in artificial intelligence (AI)-based blood and cancer diagnostic platforms, has entered the cancer diagnostic sector by launching a device to detect cervical cancer.

The company on Wednesday said it showcased miLab Cartridge CER at the four-day World Congress on Ultrasound in Obstetrics and Gynecology, which opened the day before in Paris. This device assesses the detailed stages of cervical cancer lesions based on miLab, an AI-based diagnostic testing platform.

miLab automatically conducts the microscopy examination process from blood sample preprocessing to image capture and AI analysis, producing sample analysis results in 15 minutes or less.

The device performs cell staining and analysis fully automatically for efficient and accurate testing of cervical cells. This is anticipated to cut testing time by helping medical experts diagnose cervical cancer.

By analyzing the traits of abnormal cells, the relevant ones are identified and labeled to help medical experts review abnormal cells needed for diagnosis.

miLab Cartridge CER is expected to help remove blind spots in medical care by allowing any medical facility that can collect samples screen for cervical cancer.

Of the 600,000 cases of the disease diagnosed worldwide every year, 58% are fatal.

Write to Young-Ae Lee at 0ae@hankyung.com